Lupin Digital Health (LDH), India’s leading evidence-based Digital Therapeutics (DTx) platform, today announced the launch of ...

March 14, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ...

March 14, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ...

BAUDETTE, Minn., March 14, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved an ...

ANI Pharmaceuticals (ANIP) announced that the U.S. FDA has approved an expanded label for Iluvien that includes an indication for the treatment of chronic non-infectious uveitis affecting the ...

JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) in a research report issued to clients and investors on Wednesday, MarketBeat.com reports.

Analyst Price Forecast Suggests 27.63% Upside As of March 4, 2025, the average one-year price target for ANI Pharmaceuticals is $80.75/share. The forecasts range from a low of $62.62 to a high of ...

ANI Pharmaceuticals (ANIP) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's ...

So we absolutely believe that our EYLEA HD has the potential to be the new standard-of-care in the anti-VEGF category. And there are, as we've highlighted, both in our last earning calls and at ...

Fintel reports that on March 12, 2025, JP Morgan initiated coverage of ANI Pharmaceuticals (NasdaqGM:ANIP) with a Overweight recommendation. As of March 4, 2025, the average one-year price target ...